XBI Stock Recent News

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

However, the President did not disclose when the tariffs would take effect.

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar objective, and are over-diversified. For reasons I explain here.

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

The stock market doesn't believe the president about prescription drugs.

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.

An unexpected thaw in US-China trade relations is sending US equity markets soaring this morning.

The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.